How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Clonidine Suppression Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Clonidine Suppression Test

Clonidine Suppression Test Clonidine Suppression Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Clonidine Suppression Test (...) Clonidine Suppression Test Aka: Clonidine Suppression Test , Clonidine Suppression II. Indications evaluation III. Technique Obtain initial plasma s Administer oral dose Recheck plasma s after IV. Interpretation s normally suppressed after s not suppressed in Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Clonidine Suppression Test." Click on the image (or right click) to open the source website in a new browser window. Related

2018 FP Notebook

2. Urinary clonidine suppression testing for the diagnosis of pheochromocytoma. (Abstract)

Urinary clonidine suppression testing for the diagnosis of pheochromocytoma. The diagnosis of pheochromocytoma/paraganglioma (PPGL) involves detection of elevated levels of plasma and/or 24-h urine catecholamines and/or their metabolites, including metanephrines. Although these tests are reasonably sensitive, false-positive results are often encountered. Follow-up tests can provide additional information to correctly diagnose PPGL. In this regard, the utility of the urinary clonidine (...) suppression test (UCST) remains unknown.To assess the diagnostic accuracy of the UCST in confirming or excluding PPGL, we conducted a retrospective analysis of all patients who underwent a UCST between 2000 and 2013 (n = 59; 15 PPGLs) at a single centre. Twelve-hour urine catecholamines and metanephrines were assessed before and after clonidine administration, and examined in relation to final diagnosis, PPGL or non-PPGL. Receiver operating characteristic analyses were used to identify optimal positivity

2015 Journal of Hypertension

3. Attenuation of Hemodynamic Response to Skull Pin Head Holder Insertion: Intravenous Clonidine versus Intravenous Lignocaine Infusion. Full Text available with Trip Pro

to skull pin insertion. We compared the effectiveness of i.v. clonidine infusion and i.v. lignocaine infusion in suppressing the hemodynamic response to skull pin head holder insertion.Randomized double blind study conducted with sample size - sixty patients, divided into two groups: Group C (n = 30) - clonidine i.v. dose 2 μg/kg; Group L (n = 30) - lignocaine i.v. dose 1.5 mg/kg.All patients posted for elective craniotomy belonging to American Society of Anesthesiologists (ASA) 1 and 2, age group 18 (...) Attenuation of Hemodynamic Response to Skull Pin Head Holder Insertion: Intravenous Clonidine versus Intravenous Lignocaine Infusion. Insertion of skull pin induces a significant increase in heart rate (HR), blood pressure (BP) and intracranial pressure. Alpha 2 agonist clonidine and intravenous (i.v.) lignocaine are effective in attenuating stress response. Local infiltration of pin site and scalp block with lignocaine are commonly used techniques for prevention of hemodynamic response

2019 Anesthesia, essays and researches Controlled trial quality: uncertain

4. Clonidine Suppression Test

Clonidine Suppression Test Clonidine Suppression Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Clonidine Suppression Test (...) Clonidine Suppression Test Aka: Clonidine Suppression Test , Clonidine Suppression II. Indications evaluation III. Technique Obtain initial plasma s Administer oral dose Recheck plasma s after IV. Interpretation s normally suppressed after s not suppressed in Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Clonidine Suppression Test." Click on the image (or right click) to open the source website in a new browser window. Related

2015 FP Notebook

5. Manipulating Decisiveness in Decision Making: Effects of Clonidine on Hippocampal Search Strategies Full Text available with Trip Pro

under saline control conditions. Also, consistent with previous experiments, hippocampal representations reflected the chosen path more than the unchosen path when the animal did not show VTE at the choice point. Injection of clonidine suppressed the spatial representation of the unchosen path at the choice point on VTE laps and hastened the differentiation of spatial representations of the chosen path from the unchosen path on non-VTE laps to appear before reaching the choice point. These results (...) . Researchers have speculated that clonidine limits the amount of mental search that subjects do when planning options. We test this hypothesis by measuring the mental search strategy in rats through hippocampal recordings. We find that clonidine limits the options searched by rats, suggesting that noradrenaline also plays a role in balancing exploration and exploitation in internally simulated behaviors, similar to its role in balancing exploration and exploitation in external behaviors.Copyright © 2016

2016 The Journal of Neuroscience

6. Clonidine Normalizes Levels of P50 Gating in Patients with Schizophrenia on Stable Medication. Full Text available with Trip Pro

to filtering of sensory information as a whole, by examining clonidine's effect on P50 suppression in the same group of patients.In a double-blind, placebo-controlled, randomized yet balanced cross-over design, 20 male schizophrenia patients on stable medication were assessed in a psychophysiological test battery, including a sensory gating paradigm on 5 occasions: once after oral administration of placebo and after single doses of 25, 50, 75, and 150 µg of clonidine. Their results were compared with 20 (...) age-matched healthy male volunteers, who received no treatment.Patients showed significantly reduced levels of P50 suppression in the placebo session compared with controls. All dosages of clonidine significantly diminished these deficits to such levels that they no longer differed significantly from the healthy controls (except the highest dose).This is the first study to show that even a single low dose of clonidine administered to stably medicated patients with schizophrenia not only

2014 Schizophrenia bulletin Controlled trial quality: uncertain

7. Attention deficit hyperactivity disorder: diagnosis and management

considered alternative preparations and adequate doses. [2018] [2018] F Further medication choices urther medication choices 1.7.16 Obtain a second opinion or refer to a tertiary service if ADHD symptoms in a child aged 5 years or over, a young person or adult are unresponsive to one or more stimulants and one non-stimulant. [2018] [2018] 1.7.17 Do not offer any of the following medication for ADHD without advice from a tertiary ADHD service: guanfacine [12] for adults clonidine [13] for children (...) of methylphenidate at another time of the day to extend the duration of effect). [2018] [2018] 1.7.23 Be cautious about prescribing stimulants for ADHD if there is a risk of diversion for cognitive enhancement or appetite suppression. [2018] [2018] 1.7.24 Do not offer immediate-release stimulants or modified-release stimulants that can be easily injected or insufflated if there is a risk of stimulant misuse or diversion. [2018] [2018] 1.7.25 Prescribers should be familiar with the requirements of controlled drug

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Canadian guideline for Parkinson disease

testing should be assessed by a movement disorders specialist. n No therapies are eective for slowing or stopping brain degeneration in Parkinson disease. NONMOTOR FEATURES n Botulinum toxin A helps control drooling. n Drug therapy for low blood pressure includes midodrine, udrocortisone and domperidone. n Management of depression should be tailored to the individual and their current therapy. n Dementia should not exclude a diagnosis of Parkinson disease, even if present early. n Rapid eye movement (...) to achieve a balance between providing realistic information and promoting optimism. n Families and caregivers should be informed about the condition and available support services. DIAGNOSIS AND PROGRESSION n Parkinson disease should be suspected in anyone with tremor, stiness, slowness, balance problems or gait disorders. n CT or MRI brain scanning should not be routinely used to diagnose Parkinson disease. n Patients, especially young, who request genetic testing should be assessed by a movement

2019 CPG Infobase

9. Canadian guidelines on opioid use disorder among older adults

, with an emphasis on signs of intoxication or withdrawal and the sequelae of substance use. Laboratory and other investigations (including urine drug tests) should be performed as appropriate for the medical conditions identified. Reassessment is essential and should be conducted episodically throughout long-term care. [GRADE Quality: Moderate; Strength: Strong]7 Canadian Guidelines on Opioid Use Disorder Among Older Adults QUESTION E: In older adults with or at risk for an OUD, what considerations (...) for treatment of an OUD (e.g., by 25%-50%); slow dose escalation frequency (e.g., by 25%-50%); use the lowest effective dose to suppress craving, withdrawal symptoms; and drug use; and monitor closely (especially for sleep apnea, sedation, cognitive impairment, and falls with opioid agonists). [GRADE Quality: Low; Strength: Strong] RECOMMENDATION #25: The threshold to admit an older adult with social, psychological, or physical comorbidities to either residential or hospital care for opioid withdrawal

2019 CPG Infobase

10. Phaeochromocytoma

, metanephrines, normetanephrines, and creatinine serum free metanephrines and normetanephrines plasma catecholamines genetic testing CBC serum calcium serum potassium chromogranin A clonidine suppression test MRI of the abdomen and pelvis CT scan of the abdomen and pelvis I-123 metaiodobenzylguanidine (MIBG) scintigraphy 18F-fluoro-2 deoxy-D-glucose (18F-FDG) positron emission tomography (PET) Treatment algorithm INITIAL ACUTE Contributors Authors Associate Professor of Medicine Medical College of Georgia

2018 BMJ Best Practice

11. Nitroglycerin

pressure during cardiopulmonary resuscitation in humans. 453-9 10.1016/j.jemermed.2010.02.030 Infusion of a vasopressor (...) during cardiopulmonary resuscitation (CPR) in humans increases end decompression (diastolic) arterial blood pressure, and consequently increases vital organ perfusion pressure and survival. Several vasoactive drugs have been tested alone or in combination, but their hemodynamic effects have not been investigated clinically in humans. We tested the hypothesis that epinephrine (1 (...) in Cardiovascular Therapeutics. , . Comment on [N Engl J Med. 2015] [N Engl J Med. 2015] PMID: 26510043 DOI: [Indexed for MEDLINE] Free full text Publication types 2015 14. A centrally acting antihypertensive, clonidine, combined to a venous dilator, nitroglycerin , to handle severe pulmonary edema. A patient, with known left ventricular failure presented with severe pulmonary edema, an ejection fraction of 10% to 15%, knee mottling, and lactates of 7 mM L⁻¹. He was treated with unusually high-dose

2018 Trip Latest and Greatest

13. Opioid Use Disorder - Diagnosis and Management in Primary Care

and benzodiazepines or other drugs that suppress the central nervous system requires careful medical management. Refer to or product monograph for information on side effects and drug-drug interactions. Buprenorphine/naloxone (Suboxone® ) is a 4:1 mixture of buprenorphine to naloxone that is administered sublingually. The inclusion of naloxone prevents diversion for injection. When taken as directed by the sublingual route, the buprenorphine component has high bioavailability, while naloxone has very low (...) supply), at the discretion of the treating clinician. Assessment for buprenorphine/naloxone induction It is imperative to establish the following prior to induction : Assess for common contraindications to buprenorphine/naloxone induction: allergy to components of buprenorphine/naloxone; severe respiratory distress; delirium tremens ; acute alcohol intoxication; and severe liver insufficiency. Note: Liver enzyme tests are recommended (see below) but not required to start treatment due

2018 Clinical Practice Guidelines and Protocols in British Columbia

14. Management of Stroke Rehabilitation

when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. These guidelines are not intended to represent Department of Veterans Affairs or TRICARE policy. Further, inclusion of recommendations for specific testing

2019 VA/DoD Clinical Practice Guidelines

15. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic Full Text available with Trip Pro

on epidemiology, prenatal screening, pain management, and treatment modalities of OUD in pregnancy, workshop participants were assigned to 1 of 3 breakout groups to discuss the following key issues in greater depth and to make preliminary recommendations: (1) screening and testing for substance use disorder, including OUD, in pregnancy; (2) pain management during the antepartum, intrapartum, and postpartum periods; and (3) management modalities for pregnant women with OUD. The following key findings emerged (...) from the workshop discussions: • All pregnant women should be screened for substance use at the first prenatal visit with the use of a validated questionnaire, such as the National Institute on Drug Abuse (NIDA) Quick Screen Tool. • Biologic testing, when performed, should be undertaken only with the woman’s informed consent and when its benefits outweigh any potential harms, which include those related to mandatory state reporting laws. • For opioid-naïve women, nonsteroidal anti-inflammatory

2019 Society for Maternal-Fetal Medicine

16. Comprehensive Systematic Review Summary: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders

representatives was recruited to develop this guideline. This guideline follows the methodologies outlined in the 2011 edition of the AAN’s guideline development process manual. Results: There was high confidence that the Comprehensive Behavioral Intervention for Tics was more likely than psychoeducation and supportive therapy to reduce tics. There was moderate confidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinum toxin A injections, 5-ling granule, Ningdong granule (...) referred to as premonitory urges and represent a hallmark feature of tics that may that may help to distinguish between TS and other hyperkinetic movement disorders. Not all patients report about such premonitory urges, and some patients describe both tics with and without premonitory 16 sensations. Most patients with TS are able to voluntarily suppress their tics for short periods of time (usually seconds to minutes), at the expense of mounting inner tension. 11, 12 Tics are dynamic symptoms and tend

2019 American Academy of Neurology

18. Tobacco Cessation Treatment

to quit smoking completely and offered assis- tance todoso,althoughtheneedforpharmacotherapy should be evaluated on a case-by-case basis. Asking the 2 questions that comprise the Heaviness of Smoking Index is a simple, reliable, and validated test to assess the strength of a daily smoker’s nicotine dependence (33) (Table 1). The Heaviness of Smoking Index has been shown to have equivalent or stronger validity in predicting relapse back to smoking after a quit attempt than other longer tests (...) of nicotine depen- dence (e.g., Fagerstrom Test of Nicotine Dependence, the APA Diagnostic and Statistical Manual criteria for assess tobacco use disorder) (33). Understanding the strength of someone’s nicotine dependence is important for tailoring the intensity of treatment or dose of pharmaco- therapy recommended. Other indicators of nicotine dependence include early initiation of exposure to nico- tine, dif?culty reducing and/or refraining from smoking for extended periods of time (i.e., several hours

2019 American College of Cardiology

19. Pruritus

, papulo-vesicles, blisters, pustules or wheals are observable and, according to the patient history, have been present since the onset of itch, pruritus on primarily diseased (inflamed) skin can be diagnosed. Further investigations can be performed to determine the underlying dermatosis, including skin biopsy, microbiological investigations and, in certain cases, laboratory testing (e.g. IgE, indirect immunofluorescence). 21 Secondary skin lesions encompass excoriations, ulcerations, necrosis, crusts

2019 European Dermatology Forum

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>